The (re)challenging question of erythropoiesis-stimulating agents inducing pure red cell aplasia

Nephrology Dialysis Transplantation

Volumn 23, Issue 10, 2008, Pages 3053-3055

  Summers, Shaun ^a   Holdsworth, Stephen ^a   Sharples, Edward ^b  

^a MONASH UNIVERSITY   (Australia)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Antibody; Erythropoietin; Immunology; Pure red cell aplasia

Indexed keywords

CALCINEURIN INHIBITOR; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ERYPRO; ERYTHROPOIETIN; IMMUNOGLOBULIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; STEROID; UNCLASSIFIED DRUG;

ANEMIA; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; EDITORIAL; ERYTHROCYTE TRANSFUSION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PURE RED CELL ANEMIA; TREATMENT RESPONSE;

ANEMIA; ANTIBODY FORMATION; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; RED-CELL APLASIA, PURE;

EID: 52449134863     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn326     Document Type: Editorial

References (29)

1. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
2. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
3. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
4. Dessypris E. Pure red cell aplasia. In Hoffman R, Benz EJ, Shattile F et al. (ed). Haematology: Basic Principles and Practice, 3rd edn. New York: Churchill Livingstone, 1999, 342-354
5. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antiery-thropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-475
6. Macdougall IC. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant 2005; 20(Suppl 4): iv9-iv15
7. Bennett CL, Luminari S, Nissenson AR et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 1403-1408
8. Sharma B, Bader F, Templeman T et al. Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with EPREX. Eur J Hosp Pharm 2004; 5: 86-91
9. Boven K, Knight J, Bader F et al. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant 2005; 20(Suppl 3): iii33-iii40
10. Boven K, Stryker S, Knight J et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005; 67: 2346-2353
11. Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol 2006; 24: 613-614
12. Hermeling S, Schellekens H, Crommelin DJ et al. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm Res 2003; 20: 1903-1907
13. Schellekens H. Erythropoietic proteins and antibody-mediated pure red cell aplasia: a potential role for micelles. Nephrol Dial Transplant 2004; 19: 2422
14. Mandreoli M, Finelli C, Lopez A et al. Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. Am J Kidney Dis 2004; 44: 757-761
15. Westerlund P, Kurkus J, Segelmark M. Rapid resolution of EPO-induced pure red cell aplasia after a course of immunoadsorption therapy using protein A columns. Am J Kidney Dis 2005; 45: e97-e99
16. Verhelst D, Rossert J, Casadevall N et al. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 2004; 363: 1768-1771
17. Bennett CL, Cournoyer D, Carson KR et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005; 106: 3343-3347
18. Snanoudj R, Beaudreuil S, Arzouk N et al. Recovery from pure red cell aplasia caused by anti-erythropoietin antibodies after kidney transplantation. Am J Transplant 2004; 4: 274-277
19. Vartia A, Asola MR, Tertti R et al. Two haemodialysis patients with epoetin alfa-induced pure red-cell aplasia recovered despite treatment with another epoetin preparation. Nephrol Dial Transplant 2004; 19: 1313-1316
20. Summers SA, Matijevic A, Almond MK. Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia. Nephrol Dial Transplant 2004; 19: 2137-2139
21. Campbell N, Almond M. Update on reintroduction of epoetin in a patient with pure red call aplasia. Nephrol Dial Transplant 2008; doi: 10.1093/ndt/gfn328
22. Andrade J, Taylor PA, Love JM et al. Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone. Nephrol Dial Transplant 2005; 20: 2548-2551
23. Pollock C, Johnson DW, Horl WH et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008; 3: 193-199
24. Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 2008; 3: 200-207
25. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006; 368: 947-953
26. Schellekens H. The first biosimilar epoetin: but how similar is it? Clin J Am Soc Nephrol 2008; 3: 174-178
27. Stead RB, Lambert J, Wessels D et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006; 108: 1830-1834
28. Woodburn KW, Fan Q, Winslow S et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 2007; 35: 1201-1208
29. Macdouggal I, Casadevall N, Froissart M et al. Treatment of erythropoietin antibody-mediated pure red cell aplasia with a novel synthetic peptide-based erythropoietin receptor agonist. J Am Soc Nephrol 2007; 18: 81A